Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2024 Oct 11;24(1):1267.
doi: 10.1186/s12885-024-12989-x.

The outcome of advanced and recurrent cervical cancer patients treated with first-line platinum and paclitaxel with or without indication for immune checkpoint inhibitors: the comparative study

Lan Feng  1 , Qun Shi  2 , Shujuan Wang  3 , Ye Zhao  4 , Haiyan Wu  5 , Lei Wei  6 , Qing Hao  1 , Zhaojun Cui  1 , Lin Wang  1 , Jing Zhang  1 , Dan Zhang  1 , Xinxin Zhan  1 , Jingwen Jiang  7
Affiliations
Comparative Study

The outcome of advanced and recurrent cervical cancer patients treated with first-line platinum and paclitaxel with or without indication for immune checkpoint inhibitors: the comparative study

Lan Feng et al. BMC Cancer. .

Abstract

Objective: Immune checkpoint inhibitor (ICI) therapy activates the immune system to recognize and eliminate cancer cells that have escaped surveillance. This study aimed to compare the treatment outcome of advanced and recurrent cervical cancer patients treated with first-line platinum and paclitaxel with or without ICI.

Methods: Data from 69 advanced and recurrent cervical cancer patients treated with first-line ICI plus platinum and paclitaxel (N = 33) or first-line platinum and paclitaxel (N = 36) were reviewed between March 2020 and January 2023 in this retrospective study. Patients chose treatment based on the actual disease condition, patient willingness, and medical advice. Additionally, objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) were calculated, and adverse events were gained.

Results: There was no difference in baseline data between patients receiving the two different treatments (all P > 0.05). Complete response rate (18.2% vs. 8.3%; P = 0.294), ORR (48.5% vs. 30.6%; P = 0.127), and DCR (81.8% vs. 72.2%; P = 0.345) tended to ascend in patients treated with ICI plus platinum and paclitaxel compared to those treated with platinum and paclitaxel, although there was no statistical significance. In patients treated with ICI plus platinum and paclitaxel, the median PFS was 10.3 months and the median OS was not reached. Meanwhile, the median PFS and OS were 7.7 and 16.9 months in patients treated with platinum and paclitaxel. PFS (P = 0.036) and OS (P = 0.033) were increased in patients treated with ICI plus platinum and paclitaxel versus those treated with platinum and paclitaxel, which was verified by multivariate Cox regression analyses (both P < 0.05). No difference was observed in the occurrence of adverse events between patients receiving the two different treatments (all P > 0.05).

Conclusion: First-line ICI plus platinum and paclitaxel yields better treatment responses, longer survival, and non-differential adverse events versus first-line platinum and paclitaxel in advanced and recurrent cervical cancer patients.

Keywords: Advanced and recurrent cervical cancer; Immune checkpoint inhibitors; Safety; Survival; Treatment response.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Study flow chart
Fig. 2
Fig. 2
Comparative analyses of best response, CR, ORR, and DCR in advanced and recurrent cervical cancer patients. Comparison of best responses (A), CR (B), ORR (C), and DCR (D) between patients treated with ICI plus platinum and paclitaxel and those treated with platinum and paclitaxel
Fig. 3
Fig. 3
Comparative analyses of PFS and OS in advanced and recurrent cervical cancer patients. Comparison of PFS (A) and OS (B) between patients treated with ICI plus platinum and paclitaxel and those treated with platinum and paclitaxel
Fig. 4
Fig. 4
Univariable and multivariate models for PFS in advanced and recurrent cervical cancer patients. The predictors (A) and independent predictors (B) of PFS in advanced and recurrent cervical cancer patients
Fig. 5
Fig. 5
Univariable and multivariate models for OS in advanced and recurrent cervical cancer patients. The predictors (A) and independent predictors (B) of OS in advanced and recurrent cervical cancer patients
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Rajaram S, Gupta B. Screening for cervical cancer: choices & dilemmas. Indian J Med Res. 2021;154(2):210–20. - PMC - PubMed
    1. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri: 2021 update. Int J Gynaecol Obstet. 2021;155(Suppl 1Suppl 1):28–44. - PMC - PubMed
    1. Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun (Lond). 2021;41(10):1037–48. - PMC - PubMed
    1. Menderes G, Black J, Schwab CL, Santin AD. Immunotherapy and targeted therapy for cervical cancer: an update. Expert Rev Anticancer Ther. 2016;16(1):83–98. - PubMed
    1. Kagabu M, Nagasawa T, Fukagawa D, Tomabechi H, Sato S, Shoji T, Baba T. Immunotherapy for Uterine Cervical Cancer. Healthc (Basel). 2019;7(3). - PMC - PubMed

Publication types

MeSH terms